Posted by Michael Wonder on 13 Oct 2020
Daewoong's antipyretic unable to get insurance benefits
13 October 2020 - Daewoong Pharmaceutical has failed to list Fiblast (trafermin), a burn treatment drug developed by Japan's Kaken Pharmaceutical, on the nation's reimbursement list for the fifth time.
Health Insurance Review and Assessment Service (HIRA) announced such results after a meeting of the Drug Reimbursement Evaluation Committee on Tuesday.
